

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
 or Section 30(h) of the Investment Company Act of 1940

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Gibson Neil W</u> (Last) (First) (Middle) <u>C/O TCR2 THERAPEUTICS</u> <u>100 BINNEY STREET</u> (Street) <u>CAMBRIDGE MA 02142</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>TCR2 THERAPEUTICS INC. [TCRR]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>11/07/2019</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/07/2019		J ⁽¹⁾		212,560	D	\$0.00	493,791	I	see footnote (2) ⁽²⁾
Common Stock	11/13/2019		J ⁽¹⁾		196,177	D	\$0.00	297,614	I	see footnote (2)
Common Stock	11/15/2019		J ⁽¹⁾		217,974	D	\$0.00	79,640	I	see footnote (2)
Common Stock	03/13/2020		S		52,000	D	\$6.5172 ⁽³⁾	27,640	I	see footnote (2)
Common Stock	03/16/2020		S		17,723	D	\$6.604	9,917	I	see footnote (2)
Common Stock	03/17/2020		S		3,009	D	\$6.49	6,908	I	see footnote (2)
Common Stock	03/18/2020		S		3,120	D	\$6.83	3,788	I	see footnote (2)
Common Stock	03/19/2020		S		3,140	D	\$7.41	648	I	see footnote (2)
Common Stock	03/20/2020		S		648	D	\$7.94	0	I	see footnote (2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date					
									Amount or Number of Shares				

Explanation of Responses:

1. Curative Ventures CT LLC, of which the Reporting Person is a managing member of Curative Ventures CT Ultimate Manager LLC, the general partner of Curative Ventures CT Manager, LP, the manager of Curative Ventures CT LLC, distributed these shares to its members on a pro rata basis, for no consideration.

2. The shares are held by Curative Ventures CT LLC. The Reporting Person is a managing member of Curative Ventures CT Ultimate Manager LLC, the general partner of Curative Ventures CT Manager, LP, the manager of Curative Ventures CT LLC and disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$6.415 to \$6.526, inclusive.

Remarks:

/s/ Margaret Siegel as
Attorney-in-Fact

03/27/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.